Back in September, Martin Shkreli became “the most hated man in America” when the Turing Pharma CEO moved to boost the price of a toxoplasmosis drug by 5000%.
That rather egregious example of unbridled greed immediately caused the American public as well as lawmakers in Washington to begin taking a closer look at a practice that actually happens all the time in Big Pharma even if the industry’s larger players are careful to be a bit less audacious about it than Shkreli.